A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

The drug is approved in several countries for treating eosinophil-driven diseases like severe eosinophilic asthma and eosinophilic ... COPD and an eosinophilic phenotype, marking the sixth ...

TNF-α has proinflammatory effects on eosinophils, neutrophils ... also prove to be efficacious in patients with a similar asthma phenotype. Dual inhibition of IL-4 and IL-13 with dupilumab ...

(Reuters) -The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as ... pulmonary disease (COPD) with an eosinophilic phenotype, the British drugmaker said ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

Mepolizumab is currently not approved for use in COPD in any country. First approved in 2015 for severe asthma with an eosinophilic phenotype in the US, mepolizumab is a monoclonal antibody that ...

as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits ...

The findings support incorporation of both blood eosinophils and ... with a reduced risk of asthma attacks, a counterintuitive finding that might reflect a phenotype more responsive to standard ...